PT  - JOURNAL ARTICLE
AU  - Mohamed Elmehdi Saleh
AU  - Zeinab Elmehdi Saleh
TI  - A New Mathematical Approach for the Estimation of epidemic Model Parameters with Demonstration on COVID-19 Pandemic in Libya
AID  - 10.1101/2020.07.19.20157115
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.07.19.20157115
4099  - http://medrxiv.org/content/early/2020/07/21/2020.07.19.20157115.short
4100  - http://medrxiv.org/content/early/2020/07/21/2020.07.19.20157115.full
AB  - Background The SEIR model or a variation of it is commonly used to study epidemic spread and make predictions on how it evolves. It is used to guide officials in their response to an epidemic. This research demonstrates an effective and simple approach that estimates the parameters of any variations of the SEIR model. This new technique will be demonstrated on the spread of COVID-19 in Libya.Methods A five compartmental epidemic model is used to model the COVID-19 pandemic in Libya. Two sets of data are needed to evaluate the model parameters, the cumulative number of symptomatic cases and the total number of active cases. This data along with the assumption that the cumulative number of symptomatic cases grows exponentially, to determine most of the model parameters.Results Libya’s epidemic start-date was estimated as to = −18 · 5 days, corresponding to May 5th. We mathematically demonstrated that the number of active cases follows two competing exponential distributions: a positive exponential function, measuring how many new cases are added, and a negative exponential function, measuring how many cases recovered. From this distribution we showed that the average recovery time is 48 days, and the incubation period is 15.2 days. Finally, the productive number was estimated as R0 = 7·6.Conclusions With only the cumulative number of cases and the total number of active cases of COVID19, several important SEIR model parameters can be measured effectively. This approach can be applied for any infectious disease epidemic anywhere in the world.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo funding was provided for this workAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Our work does not include any human subjectAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data are available publicly